SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

Abstract

Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar. Methods All SARS-CoV-2 antibody-positive persons from April 16 to December 31, 2020 with a PCR-positive swab ≥14 days after the first-positive antibody test were investigated for evidence of reinfection. Viral genome sequencing was conducted for paired viral specimens to confirm reinfection. Incidence of reinfection was compared to incidence of infection in the complement cohort of those who were antibody-negative. Findings Among 43,044 antibody-positive persons who were followed for a median of 16.3 weeks (range: 0–34.6), 314 individuals (0.7%) had at least one PCR positive swab ≥14 days after the first-positive antibody test. Of these individuals, 129 (41.1%) had supporting epidemiological evidence for reinfection. Reinfection was next investigated using viral genome sequencing. Applying the viral-genome-sequencing confirmation rate, the incidence rate of reinfection was estimated at 0.66 per 10,000 person-weeks (95% CI: 0.56–0.78). Incidence rate of reinfection versus month of follow-up did not show any evidence of waning of immunity for over seven months of follow-up. Meanwhile, in the complement cohort of 149,923 antibody-negative persons followed for a median of 17.0 weeks (range: 0–45.6), incidence rate of infection was estimated at 13.69 per 10,000 person-weeks (95% CI: 13.22–14.14). Efficacy of natural infection against reinfection was estimated at 95.2% (95% CI: 94.1–96.0%). Reinfections were less severe than primary infections. Only one reinfection was severe, two were moderate, and none were critical or fatal. Most reinfections (66.7%) were diagnosed incidentally through random or routine testing, or through contact tracing. Interpretation Reinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months. Funding Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, and the Genomics Core, all at Weill Cornell Medicine-Qatar, the Ministry of Public Health, Hamad Medical Corporation, and the Qatar Genome Programme.

Behavioural responses to Covid-19 health certification: a rapid review

“…Regardless of the basis for any Covid-19 status certificate issued, certification will indicate that the holder has been deemed to pose a lower risk of infection and perhaps transmission of the virus than those without a certificate. At the time of writing, evidence suggests that protection from further infection having had the virus is very high for ~ 7 months [ 68 , 69 ], and that current vaccines can cut household transmission of known variants by half [ 70 ]. Vaccination and prior infection therefore mean risks may indeed be significantly lower.…”

Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study

“…Within a cohort of over 3.2 million US patients, Harvey et al found a ratio of 0.10 of positive PCRs among those with vs. those without positive antibody test at baseline (for tests performed > 90 days after baseline) [ 8 ]. Among over 43000 people with a positive antibody test (median follow-up 4 months) from Qatar, the estimated efficacy of natural infection against re-infection was above 90% [ 9 ]. Also, data from a population-based study (> 500,000 people) conducted in Denmark suggest that protection after natural SARS-CoV-2 infection was 80% after 6 months (but only 47% for adults aged 65 years or older) [ 10 ].…”

Persistent while declined neutralizing antibody responses in the convalescents of COVID-19 across clinical spectrum during the 16 months follow up

“…Key question to address is what level of the neutralizing antibody response could provide protection against infection or reinfection. Several large cohort studies have shown that antibody-mediated immunity could provide strong protection from reinfection in seropositive individuals up to seven months after infection with protection efficacy varied from 80.5% to 95% [48][49][50] . A recent study suggested that the estimated neutralization level for 50% protection against detectable SARS-CoV-2 infection was 20.2% of the mean convalescent level, and the estimated neutralization level required for 50% protection from severe infection was about 3% of the mean convalescent level 51 .…”